Pfizer
PFE
$24.48
+1.28%
Pfizer is one of the world's largest pharmaceutical firms, developing and manufacturing prescription drugs and vaccines, with top sellers including Prevnar 13, Vyndaqel, and Eliquis. As a global pharmaceutical giant with roughly $60 billion in annual sales, it holds a dominant position in the industry, though it faces patent cliffs and competitive pressures. The current investor narrative centers on Pfizer's pipeline transformation, particularly its promising weight-loss drug berobenatide, which could challenge Eli Lilly and Novo Nordisk, while the company navigates a CFO transition and clinical trial setbacks that have tested investor confidence in its 2026 outlook.…
PFE
Pfizer
$24.48
Related headlines
Investment Opinion: Should I buy PFE Today?
Rating: Hold. Pfizer is a deep value play with a forward P/E of 8.5x, but the lack of near-term growth catalysts and recent net losses warrant caution. The analyst consensus is a Buy, but the implied target based on forward P/E suggests downside from current levels. Supporting evidence includes a 70% gross margin, $9.08B in free cash flow, a 6.9% dividend yield, and a 43% valuation discount to the industry median. However, the most recent quarter's net loss of $1.65B and revenue decline of 1.2% YoY highlight operational challenges. The biggest risks are pipeline execution failure, dividend cut, and continued revenue erosion. This Hold would upgrade to Buy if the forward P/E compresses below 7x or if berobenatide shows phase 3 success, and downgrade to Sell if revenue growth turns negative for two consecutive quarters. Overall, Pfizer appears undervalued on a forward basis but fairly valued on trailing earnings, reflecting the market's skepticism about the earnings recovery.
Sign up to view all
PFE 12-Month Price Forecast
Pfizer's outlook is balanced between deep value and operational headwinds. The forward P/E of 8.5x is attractive, but the recent net loss and revenue decline temper enthusiasm. The base case of flat revenue and gradual pipeline progress is most likely, keeping the stock range-bound. A bullish stance would require concrete pipeline catalysts, while a bearish stance would materialize if earnings disappoint or the dividend is cut. The neutral stance reflects the uncertainty around the timing of a growth inflection.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Pfizer's 12-month outlook, with a consensus price target around $31.82 and implied upside of +30.0% versus the current price.
Average Target
$31.82
11 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
11
covering this stock
Price Range
$20 - $32
Analyst target range
Pfizer is covered by 11 analysts, with a consensus leaning bullish. Recent ratings include multiple Buy ratings from Guggenheim, HSBC, Argus Research, and Freedom Broker, while Cantor Fitzgerald and B of A Securities maintain Neutral/Equal Weight. The average estimated EPS for the current fiscal year is $2.30, with a range of $2.19 to $2.41, and average revenue estimate of $53.5 billion. The consensus recommendation is a Buy, and the average price target is not explicitly provided in the data, but based on the forward P/E of 8.5x and estimated EPS of $2.30, the implied target price is approximately $19.55, which is 19% below the current price of $24.17, suggesting downside. However, this calculation is approximate; actual analyst targets may vary. The target range for EPS estimates is relatively narrow ($2.19 to $2.41), indicating moderate conviction in the earnings outlook. The high estimate of $2.41 assumes successful pipeline execution and margin expansion, while the low estimate of $2.19 prices in continued revenue pressure and patent cliff headwinds. Recent upgrades from Argus (Hold to Buy) and consistent Buy ratings from multiple firms suggest improving sentiment, but the CFO transition and clinical trial miss have introduced uncertainty. The wide spread in analyst actions (some upgrading, some neutral) reflects the binary nature of Pfizer's pipeline-driven outlook.
Bulls vs Bears: PFE Investment Factors
Pfizer presents a classic value-versus-value-trap debate. On the bull side, the forward P/E of 8.5x is deeply discounted relative to the industry, supported by strong free cash flow of $9.08B and a promising obesity pipeline in berobenatide. On the bear side, revenue is stagnating with a -1.2% YoY decline, the company posted a net loss in the most recent quarter, and the dividend payout ratio of 126% raises sustainability concerns. The single most important tension is whether the pipeline (especially berobenatide) can offset patent cliff headwinds and return the company to sustainable earnings growth. Currently, the bear case has slightly stronger evidence given the lack of near-term growth catalysts and the stock's persistent downtrend, but the valuation discount provides a compelling risk/reward for patient investors.
Bullish
- Compelling Forward Valuation: Pfizer trades at a forward P/E of 8.5x, a 43% discount to the Drug Manufacturers industry median of ~15x. This deep discount implies the market has already priced in significant pessimism, offering a margin of safety if earnings recover as expected.
- Strong Free Cash Flow Generation: Trailing twelve-month free cash flow stands at $9.08 billion, providing ample coverage for capital expenditures ($0.85B in Q4) and dividends ($2.45B paid in Q4). This cash flow supports the 6.9% dividend yield and provides financial flexibility for pipeline investment.
- Promising Pipeline Catalyst in Obesity: Pfizer's monthly-injection weight-loss drug berobenatide has shown encouraging data, potentially challenging Eli Lilly and Novo Nordisk in the massive obesity market. This represents a multi-billion-dollar opportunity that could reignite growth.
- Healthy Gross Margin and Cash Position: Gross margin remains robust at 70.0%, indicating strong pricing power and cost control in manufacturing. The current ratio of 1.16 and debt-to-equity of 0.78 suggest a manageable balance sheet with adequate liquidity.
Bearish
- Stagnant Revenue and Patent Cliff Risks: Revenue declined 1.2% year-over-year in the most recent quarter to $17.56 billion, with no clear growth trend. Key products face patent expirations and competition, notably from Merck's pneumococcal vaccine label expansion, pressuring the top line.
- Negative Net Income and High Payout Ratio: The most recent quarter reported a net loss of $1.65 billion (net margin -9.4%), swinging from a profit of $3.54 billion in the prior quarter. The dividend payout ratio of 126% indicates dividends exceed net income, relying on cash flow and potentially unsustainable.
- Sustained Price Downtrend and Underperformance: The stock is down 6.2% over the past year versus the S&P 500's 20.6% gain, with a 1-year relative strength of -26.9%. The current price of $24.17 is near the 52-week low of $23.11, reflecting persistent selling pressure.
- Leadership Uncertainty and Clinical Setbacks: A CFO transition and a clinical trial miss have tested investor confidence in the 2026 outlook. Recent news highlights a 'significant clinical trial failure' and leadership changes, adding execution risk to an already challenged narrative.
PFE Technical Analysis
Pfizer is in a sustained downtrend, with the stock declining 6.2% over the past year compared to the S&P 500's 20.6% gain. The current price of $24.17 sits at 84% of its 52-week range (low $23.11, high $28.75), near the bottom of the range, suggesting the stock is oversold and potentially offering a value opportunity, though the downtrend remains intact. The 1-year relative strength of -26.9% underscores significant underperformance versus the market. Short-term momentum is decisively bearish, with 1-month and 3-month price changes of -5.6% and -10.2%, respectively, accelerating the decline. This divergence from the longer-term trend (1-year -6.2%) indicates a sharp pullback, potentially signaling a capitulation phase or a mean-reversion setup if the stock stabilizes. The 1-month relative strength of -9.7% versus the S&P 500 confirms broad-based selling pressure. The 52-week low of $23.11 provides critical support, while resistance sits at the 52-week high of $28.75. A breakdown below $23.11 would signal further downside, while a breakout above $28.75 would indicate a trend reversal. Beta of 0.307 suggests the stock is significantly less volatile than the market, meaning it tends to decline less in downturns but also rallies less in upswings, which is consistent with its defensive pharmaceutical profile.
Beta
0.31
0.31x market volatility
Max Drawdown
-17.1%
Largest decline past year
52-Week Range
$23-$29
Price range past year
Annual Return
-4.6%
Cumulative gain past year
| Period | PFE Return | S&P 500 |
|---|---|---|
| 1m | -6.6% | +1.0% |
| 3m | -9.7% | +7.9% |
| 6m | -4.3% | +8.5% |
| 1y | -4.6% | +20.1% |
| ytd | -2.8% | +9.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
PFE Fundamental Analysis
Pfizer's revenue trajectory is stagnating, with the most recent quarterly revenue of $17.56 billion reflecting a 1.2% year-over-year decline. Over the past four quarters, revenue has fluctuated between $13.7 billion and $17.8 billion, showing no clear growth trend as the company laps pandemic-related product declines. The Biopharma segment generated $30.6 billion in trailing revenue, but the overall top line is pressured by patent expirations and competition, notably from Merck's pneumococcal vaccine label expansion. The investment case hinges on pipeline catalysts like berobenatide to reignite growth. Profitability is mixed: the company reported a net loss of $1.65 billion in the most recent quarter (net margin -9.4%), swinging from a profit of $3.54 billion in the prior quarter. Gross margin remains healthy at 70.0%, but operating margin compressed to 21.0% from 33.7% a year earlier, reflecting higher R&D spending ($3.42 billion) and restructuring costs. The trailing twelve-month net income of $0.05 per share is barely positive, indicating that Pfizer is only marginally profitable on an annual basis, though the Q3 2025 quarter showed strong profitability. The balance sheet is moderately leveraged with a debt-to-equity ratio of 0.78 and a current ratio of 1.16, indicating adequate liquidity. Free cash flow over the trailing twelve months was $9.08 billion, providing ample coverage for capital expenditures ($0.85 billion in Q4) and dividends ($2.45 billion paid in Q4). ROE of 9.0% is reasonable but below historical highs, and the company's ability to generate cash internally supports its dividend, though the payout ratio of 126% suggests dividends exceed net income, relying on cash flow.
Quarterly Revenue
$17.6B
2025-12
Revenue YoY Growth
-1.16%
YoY Comparison
Gross Margin
69.97%
Latest Quarter
Free Cash Flow
$9.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is PFE Overvalued?
Since net income is positive on a trailing basis (EPS $0.05), we lead with the P/E ratio. The trailing P/E of 18.3x is elevated due to depressed earnings, while the forward P/E of 8.5x reflects expectations of a sharp earnings recovery (estimated EPS $2.30). The wide gap between trailing and forward P/E implies the market expects a significant rebound in profitability, likely driven by pipeline progress and cost discipline. Compared to the industry average (Drug Manufacturers - General), Pfizer's forward P/E of 8.5x is at a discount to the sector median of approximately 15x, representing a 43% discount. This discount is justified by Pfizer's stagnant revenue growth and patent cliff risks, but it also suggests the market is pricing in a pessimistic scenario. The P/S ratio of 2.3x is below the 5-year average of 3.5x, indicating the stock is cheap on a sales basis. Historically, Pfizer's trailing P/E has ranged from 7x to 93x over the past five years. The current trailing P/E of 18.3x is near the lower end of its historical range, suggesting the stock is not expensive relative to its own history. However, the low P/E is partly due to depressed earnings; on a normalized earnings basis, the multiple may be higher. The P/B ratio of 1.64x is near the low end of its 5-year range (1.5x to 4.3x), implying the market is valuing the company at a discount to book value, which could indicate a value trap or a buying opportunity depending on future earnings power.
PE
18.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -21x~1666x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Pfizer's most immediate financial risk is its negative net income of $1.65 billion in the most recent quarter, swinging from a profit of $3.54 billion in Q3 2025. The dividend payout ratio of 126% means dividends exceed net income, relying on free cash flow of $9.08B, which could be pressured if cash flow declines. Revenue is stagnating at $17.56B (down 1.2% YoY), with no clear growth trajectory as the company laps pandemic product declines. Operating margin compressed to 21.0% from 33.7% a year earlier due to higher R&D spending ($3.42B) and restructuring costs, indicating margin pressure.
FAQ
The primary risk is pipeline failure, particularly if berobenatide fails in phase 3, which would remove the key growth catalyst and could lead to a dividend cut. Financial risk includes the 126% payout ratio, meaning dividends exceed net income, though free cash flow currently covers them. Competitive risk from Merck's pneumococcal vaccine expansion threatens Prevnar 13 market share. Macro risk is low given a beta of 0.307, but the stock is sensitive to interest rates due to its high dividend yield. The most severe risk is a dividend cut, which could trigger a sell-off to the 52-week low of $23.11 or below.
The 12-month forecast is range-bound with a base case target of $24-$28, reflecting flat revenue and gradual pipeline progress. The bull case (25% probability) targets $28-$32, driven by berobenatide success and multiple expansion. The bear case (25% probability) targets $20-$23, assuming pipeline failure and a dividend cut. The most likely scenario is the base case, where EPS meets consensus of $2.30 and the stock trades at a forward P/E of ~10x. Analyst consensus is a Buy, but the implied target based on forward P/E suggests limited upside from current levels.
Pfizer appears undervalued on a forward basis, with a forward P/E of 8.5x versus the industry median of 15x, representing a 43% discount. The P/S ratio of 2.3x is below its 5-year average of 3.5x, and the P/B of 1.64x is near the low end of its historical range. However, the trailing P/E of 18.3x is elevated due to depressed earnings, indicating that the market is pricing in a sharp earnings recovery. On a normalized earnings basis, the stock is fairly valued to slightly undervalued, but the discount reflects real risks including patent cliffs and pipeline uncertainty.
Pfizer offers a compelling risk/reward for patient investors willing to wait for pipeline catalysts. The forward P/E of 8.5x is a 43% discount to the industry, and the 6.9% dividend yield is well-covered by free cash flow of $9.08B. However, the stock has underperformed the market by 26.9% over the past year, and the most recent quarter showed a net loss of $1.65B. It is a good buy for income-focused investors who can tolerate near-term volatility, but growth-oriented investors may find better opportunities elsewhere until pipeline progress becomes clearer.
Pfizer is better suited for long-term investment due to its low beta of 0.307, high dividend yield of 6.9%, and the binary nature of pipeline catalysts. Short-term trading is risky given the stock's persistent downtrend and negative momentum (-5.6% in the past month). The recommended minimum holding period is 12-18 months to allow pipeline developments to materialize. For income investors, the dividend provides a cushion, but capital appreciation depends on successful pipeline execution. The stock is not suitable for short-term traders seeking quick gains.